Skip to main content
. 2022 Aug 15;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411

Figure 1. Study Flow Diagram.

Figure 1.

Inclusion in the overall modified full analysis set (mFAS) population required a positive polymerase chain reaction test from a central laboratory at baseline; the placebo groups are pooled. The seronegative mFAS population is a proper subset of the overall mFAS, in which patients were also required to be seronegative at baseline. CAS indicates casirivimab; IMD, imdevimab.

aThese numbers include the pooled (intravenous [IV] and subcutaneous [SC]) placebo group members (98 in the overall mFAS and 77 in the seronegative mFAS).